Long-term response on letrozole for gastric cancer
A case report
Yuuki Iida, MD, PhD,∗a, Kumiko Hongo, MD, PhD, Takanobu Onoda, MD, Yusuke Kita, MD, PhD, Yukio Ishihara, MD, PhD, Naoki Takabayashi, MD, Ryo Kobayashi, MD, Ken Kuriki, MD, PhD, Takeyuki Hiramatsu, MD, PhD

Abstract
Rationale: Hormone therapies, particularly those targeting estrogen and its receptors, are a key treatment modality for patients with estrogen receptor (ER)-positive breast or ovarian cancer. Some gastric cancers (GCs) express ERs and preclinical studies suggest the potential of estrogen-targeting hormone therapy on GC; however, the clinical relevance of this hormone therapy on GC treatment has not been well elucidated.

Patient concerns: An 80-year-old female was admitted to our department with hypogastric pain and vomiting. Computed tomography demonstrated small bowel obstruction, and laparotomy after bowel decompression revealed peritoneal dissemination consisting of a poorly-differentiated adenocarcinoma. Intestinal bypass between the ileum and transverse colon was performed.

Diagnoses: The tumor was ER- and mammaglobin-positive, indicating that it originated from a breast cancer. Diagnostic imaging revealed no evidence of breast cancer; however, right axillary ER- and mammaglobin-positive lymphadenopathy was found.

Interventions: The patient received hormone therapy using letrozole based on a clinical diagnosis of occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis.

Outcomes: The patient remained disease free until 37 months but deceased at 53 months from the onset of disease. An autopsy revealed no tumor cells in the right breast tissue; however, there was a massive invasion of cancer cells in the stomach.

Lessons: A patient with ER positive GC with peritoneal dissemination and right axillary lymph node metastasis presented remarkable response to letrozole. The long-term survival obtained using letrozole for a patient with GC with distant metastasis suggests the potential of estrogen targeting hormone therapies for GC.

Abbreviations: CK = cytokeratin, CT = computed tomography, CUP = cancer of unknown primary, ER = estrogen receptor, GC = gastric cancer.

Keywords: case report, estrogen receptor, gastric cancer, hormone therapy, letrozole

1. Introduction
Currently, systemic therapies for unresectable locally advanced, recurrent or metastatic gastric cancer (GC) include chemotherapy, molecular targeted therapies and a limited variation of molecular targeted therapies.[1] Preferred regimens for first-line therapy are a combination of fluoropyrimidines (e.g., fluorouracil or capecitabine) and platinum-based agents (e.g., cisplatin or oxaliplatin). ECF (epirubicin, cisplatin, and fluorouracil), DCF (docetaxel, cisplatin, and fluorouracil) and their modifications are also applicable for the first-line therapy.[1] Preferred second-line therapy is a combination of taxanes (paclitaxel or nab-paclitaxel) and ramucirumab.[13] Other chemotherapeutic agents, such as irinotecan, docetaxel, or tricolor adipic acid (tipiracil), are also candidates for second- or later-line treatment.[1,4] Besides these chemotherapies, molecular targeted therapies have been recently applied in clinical practice; trastuzumab for HER2-positive GC, ramucirumab targeting VEGF2R used in second-line treatment with taxanes, and nivolumab, a monoclonal anti-programmed death-1 antibody, known as immune checkpoint inhibitor.[1,5] Despite these advances in chemotherapies and molecular targeted therapies for GC treatment, many of the clinical trials demonstrated median overall survival less than 18 months for unresectable locally advanced, recurrent, or metastatic GC; thus, alternative therapies need to be investigated to improve the prognosis of this disease.

Recently, many investigators have explored the potential of applying hormone therapy on GC, particularly targeting estrogen and estrogen receptor (ER).[6–9] Hormone therapy targeting
estrogen consists of an aromatase inhibitor, an ER inhibitor (tamoxifen), and a selective ER degrader (fulvestrant).\[10\] Aromatase inhibitor, such as letrozole, exemestane, or anastrozole, are applied for the treatment of breast cancer in postmenopausal women. On the contrary, tamoxifen is mainly selected for premenopausal women with breast cancer.\[10\] Although several reports have documented the effect of hormonal replacement therapy (HRT) or tamoxifen use on GC development,\[11–16\] studies investigating the potential of estrogen targeting hormone therapy on GC treatment are currently very limited, and there are no recent reviews on this topic. Herein, we report a case of GC that presented with a long-term response on letrozole and reviewed recent progress in estrogen targeting hormone therapy for GC.

2. Case report

An 80-year-old female, who underwent right hemicolecotomy with lymph node dissection for ascending colon cancer one and half year ago (moderately-differentiated adenocarcinoma, Stage IIIa, UICC eighth edition), was admitted to our department with hypogastric pain and vomiting. The patient had slight anemia (Hb 10.3g/dL) and high CA125 (902U/mL), but CEA (3.1ng/mL), CA19-9 (20.2 U/mL), CA72-4 (0.9 U/mL), and CA15-3 (11.4 U/mL) were within normal range. Computed tomography (CT) demonstrated small bowel obstruction and ascites in the pelvis and on the liver surface (Fig. 1A). After decompression of the small bowel with long-tube insertion, injection of contrast medium through the tube demonstrated a stenosed segment in the small bowel (Fig. 1B). The patient underwent laparotomy, which revealed peritoneal dissemination of a poorly differentiated adenocarcinoma diagnosed by intraoperative rapid diagnosis. For relieving the small bowel obstruction due to dissemination, intestinal bypass between the ileum and transverse colon was performed. The patient experienced no postoperative complication and started oral intake 4 days after the surgery.

Histopathological examination confirmed proliferation of a poorly-differentiated adenocarcinoma in the resected specimen from the dissemination. Its feature was distinct from moderately-differentiated adenocarcinoma observed in the previous ascending colon cancer (Fig. 1C and 1D), suggesting the presence of an independent primary tumor. Immunohistochemical examination demonstrated positive results for cytokeratin (CK) 7, CK19, ER, progesterone receptor, and mammaglobin, whereas negative for CK20, GCDFP15, TTF1, or CDX-2 (Fig. 1E and 1F). The presence of ER, progesterone receptor, and mammaglobin expression indicated that the tumor originated from breast cancer. Ultrasonography, CT, and magnetic resonance imaging

Figure 1. ER-positive poorly-differentiated adenocarcinoma from peritoneal dissemination. (A). Contrast-enhanced CT scan of the abdomen showing dilated small bowel (arrows) and ascites on the liver surface (arrowhead). (B). Gastrografin contrast radiography through long-tube showing a stenosed segment in the small bowel. Histopathological findings showing the proliferation of poorly-differentiated adenocarcinoma in the disseminated tissue (C, ×200) and proliferation of moderately-differentiated adenocarcinoma in the ascending colon cancer (D, ×200). Immunohistochemical examination showing positive results for ER (E, ×200) and mammaglobin (F, ×200) from the disseminated tissue.
revealed lymphadenopathy in the right axilla (Fig. 2A and 2B); however, there was no evidence of breast cancer. The patient underwent surgical removal of the lymph node under local anesthesia, and histopathological and immunohistochemical examination demonstrated a similar pattern from the peritoneal dissemination (ER and mammaglobin-positive, Figures 2C and 2D). Based on these findings, we made a diagnosis of occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis. Additionally, 18F-fluorodeoxyglucose positron emission tomography (PET)/CT, esophagogastroduodenoscopy, and colonoscopy revealed no evidence of other primary tumors. The patient and her family declined intensive chemotherapy for breast cancer to avoid severe adverse effects and decided to receive hormone therapy using letrozole for ER-positive breast cancer. Ascites diminished and CA125 rapidly decreased (Fig. 3A), and the patient remained free of disease until 37 months after the treatment without experiencing severe adverse effects. CT scan revealed ascites, pleural effusion, and multiple bone metastasis at 48 months (Fig. 3B and 3C), and she deceased from the cancer at 53 months.

An autopsy was performed to confirm the clinical diagnosis and treatment. The autopsy revealed no tumor cells in the right breast tissue; however, massive invasion and proliferation of poorly-differentiated adenocarcinoma was observed in the stomach (Fig. 4A and 4B), indicating that the tumor originated from GC. Interestingly, the tumor cells presented positive mammaglobin expression (Fig. 4C); however, no cells expressed ER, suggesting that the tumor cells acquired resistance during hormone therapy under drug pressure. The final diagnosis was ER-positive GC with peritoneal dissemination and right axillary lymph node metastasis; therefore, we concluded that GC presented remarkable response to letrozole.

### 3. Discussion

#### 3.1. ER expression in GC

The prevalence of ER-positive GC varies between literatures and differs between ER subtypes, namely ERα and ERβ. Both ERs are members of a superfamily of nucleus receptors and exert their functions through a genomic pathway; estrogen binding promotes ER dimerization, the complex translocates into the nucleus, binds to estrogen response elements on the genomic DNA with transcriptional co-activators or co-repressors, and regulates DNA transcription of specific genes. There also exists a non-genomic pathway; ERs interact with other signaling molecules involved in MAPK or PI3K/Akt pathways. Interestingly, at sub-saturating hormone levels, ERβ functions as an inhibitor/competitor of ERα transcriptional activity, suggesting the relative expression level of the ER subtypes.
determine cellular responses to ER agonists and antagonists. Accordingly, the association between ER expression and clinicopathological features of GC differs between ERa and ERb. There exist 3 isoforms for ERa, namely ERa66, ERa46, and ERa36, and their difference lies in their distinct transcriptional activation factors (AF-1 and AF-2). Of clinical relevance, ERa66 expression is associated with diffuse type GC, shorter DFS, or poor OS, whereas ERa36 expression is correlated with lymph node metastasis in clinical samples. Five different isoforms, ERb1- ERb5, have been identified for ERb. Contrary to ERa, ERb expression is associated with lower tumor stage, intestinal type, and free of recurrence. Another study demonstrated the absence of ERb as an independent factor for poor OS, indicating the suppressive effect of ERb on GC progression. These results suggest that ERa and ERb have distinct effects on GC progression and that distinguishing ER subtype is essential. A recent meta-analysis also demonstrated that high ERa predicted poor OS and lower tumor differentiation, while high ERb suggested favorable OS and higher tumor differentiation, further supporting the distinct function between ER subtypes in GC.

The prevalence of ER-positive GC ranges between 4.3% to 49.6% for ERa and 32% to 93.5% for ERb. The positivity rates vary between studies, probably due to the
difference in clinical background and evaluation (e.g., staining procedures and threshold for positive ER staining). As a considerable number of GC cases are ER positive, preclinical and clinical studies investigating the interaction between estrogen, ER, and GC potentially provides us additional strategies to overcome GC with metastasis.

3.2. Effect of HRT and tamoxifen use on GC development

In contrast to a limited number of investigations on hormone therapy in the treatment of GC, more reports have referred to the risk of GC development after HRT or tamoxifen use (an inhibitor of ER). Epidemiologic studies demonstrating male dominance of GC suggest a possible role of sex hormones on the oncologic risk of GC. A population-based study from Shanghai indicated that female hormones play a protective role in GC risk. Another population-based study from Sweden also demonstrated that the incidence of esophageal cancer and GC decreased with HRT. These results indicate the protective role of estrogen on GC risk. Conversely, tamoxifen use might accelerate GC progression or increase the GC risk based on population-based studies; however, a recent meta-analysis demonstrated that there was no substantial GC risk with tamoxifen use in female patients. These studies refer to the preventive effect of HRT or potential risk of tamoxifen use on the development of GC; the effect of long-term exposure to estrogen or tamoxifen on the oncogenesis or progression of GC.

3.3. Potential of hormone therapy for GC treatment

Several preclinical studies using GC cell lines suggest the potential of applying estrogen-targeting hormone therapy on GC. One of the ER-targeting agents, tamoxifen, has an anti-proliferative effect on GC cell lines. Stimulation of GC cell lines with 17β-estradiol (E2) promoted proliferation, up-regulated ER-α36 mRNA expression, and repressed cell apoptosis. Conversely, tamoxifen treatment repressed proliferation, downregulated ER-α36 mRNA expression, and induced apoptosis, indicating the suppressive effect of tamoxifen on GC growth. Exemestane, an inhibitor of aromatase enzymatic function, also demonstrated that the incidence of esophageal cancer and GC decreased with HRT. These results indicate the protective role of estrogen on GC risk. Conversely, tamoxifen use might accelerate GC progression or increase the GC risk based on population-based studies; however, a recent meta-analysis demonstrated that there was no substantial GC risk with tamoxifen use in female patients. These studies refer to the preventive effect of HRT or potential risk of tamoxifen use on the development of GC; the effect of long-term exposure to estrogen or tamoxifen on the oncogenesis or progression of GC.

3.4. Applying hormone therapy on cancer of unknown primary with positive ER expression

The initial diagnosis in our case was occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis; however, the origin of the tumor was GC at the final diagnosis. Immunohistochemical examination is indispensable to precisely specify the origin of the tumor for patients presenting a non-stereotypical clinical course as in this case or those with cancer of unknown primary (CUP). Breast cancer has multiple specific immunohistochemical markers, such as GATA3, mam-maglobin, and GCDFP-15; however, there are no specific markers strongly recommended or commonly used for GC, making it difficult to specify the origin in GC cases. Five percent of CUP cases are originating from GC based on autopsy; and they are potential candidates for hormone therapy when ER expression is positive. Currently, estrogen-targeting hormone therapy for ER-positive CUP is not recommended unless breast cancer is expected as an origin; however, exploring GC specific markers as well as investigating estrogen-targeting hormone therapy for GC potentially improves the prognosis of CUP that are actually originated from GC.

4. Conclusions

We report a case of ER-positive GC with peritoneal dissemination and right axillary lymph node metastasis that displayed remarkable response on letrozole and long-term survival. Accumulation of GC case series treated with hormone therapy and further preclinical studies are encouraged for the wide application of hormone therapy on GC, and eventually, to facilitate clinical trials.

Author contributions

Conceptualization: Yuuki Iida, Kumiko Hongo, Takanobu Onoda, Ryo Kobayashi. Data curation: Yuuki Iida, Kumiko Hongo, Yusuke Kita, Naoki Takabayashi, Ken Kuriki. Supervision: Yukio Ishihara, Ken Kuriki, Takeyuki Hiramatsu. Writing – original draft: Yuuki Iida, Kumiko Hongo, Yusuke Kita, Yukio Ishihara, Naoki Takabayashi.
Writing – review & editing: Yuuki Iida, Kumiko Hongo, Takenobu Onoda, Yusuke Kita, Ryo Kobayashi, Ken Kuriki, Takeyuki Hiratsume.

References

[1] Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016; clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 2016;doi:10.6004/jnccn.2016.0137.

[2] Koizumi W, Morita S, Sakata Y. A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Gemcathor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol 2015;doi:10.1093/jjco/hyu205.

[3] Bando H, Shimodaira H, Fujitani K, et al. A Phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 2018;doi:10.1016/j.ejca.2017.11.032.

[4] Shitara K, Doi T, Dvorkin M, et al. Triplarudine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;doi:10.1016/S1470-2045(18)30739-3.

[5] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;doi:10.1016/S0140-6736(17)31827-5.

[6] Hadi AEL, AL-Momani H, Edwards P. An effect of letrozole on gastric cancer? J Gastric Cancer 2011;doi:10.5230/jgc.2011.11.3.180.

[7] Yang JC, Chang N, Wu DC, et al. Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer. J Cell Mol Med 2019;doi:10.1111/jcmm.14605.

[8] Yi JH, Do IG, Jang J, et al. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep 2014;doi:10.1038/srep07592.

[9] Wang X, Chen Q, Huang X, et al. Effects of 17-beta-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α expression. Oncol Lett 2019;doi:10.3892/ol.2019.10983.

[10] Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines—cancer. J Natl Compr Cancer Netw 2016;doi:10.6004/jnccn.2016.0078.

[11] Lindblad M, García Rodríguez LA, Chandanos E, et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006;doi:10.1038/sj.bjc.6602906.

[12] Freedman ND, Chow WH, Gao YT, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 2007;doi:10.1136/gut.2007.129411.

[13] Brusselaers N, Maret-Ouda J, Konings P, et al. Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer 2017;doi:10.1002/ijc.30588.

[14] Chandanos E, Lindblad M, Rubio CA, et al. Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer 2008;doi:10.1016/j.ejca.2008.02.049.

[15] Chandanos E, Lindblad M, Jia C, et al. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 2006;doi:10.1038/sj.bjc.6603214.

[16] Chen S, Liu H, Li J, et al. Risk of gastric and colorectal cancer after tamoxifen use for breast cancer: a systematic review and meta-analysis. J Clin Gastroenterol 2015;doi:10.1097/MCG.0000000000002622.

[17] Rahman MSU, Cao J. Estrogen receptors in gastric cancer: advances and perspectives. World J Gastroenterol 2016;doi:10.3748/wg.v22.i8.2475.

[18] Chen C, Gong X, Yang X, et al. The roles of estrogen and estrogen receptors in gastrointestinal disease (Review). Oncol Lett 2019;doi:10.3892/ol.2019.10983.

[19] Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;doi:10.1016/S0092-8674(02)08100-x.

[20] Yokozaki H, Takekura N, Takanashi A, et al. Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis. Vuchows Arch A Pathol Anat Histopathol 1988;doi:10.1007/BF00783021.

[21] Xu CY, Guo JL, Jiang ZN, et al. Prognostic role of estrogen receptor α and estrogen receptor β in gastric cancer. Ann Surg Oncol 2010;doi:10.1245/s10434-010-1031-2.

[22] Deng H, Huang X, Fan J, et al. A variant of estrogen receptor-α, ER-α36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep 2010;doi:10.3892/or-00000842.

[23] Ryu WS, Kim JH, Jang YJ, et al. Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol 2012;doi:10.1002/jso.23097.

[24] Zhang D, Xu J, Yi Y, et al. The prognostic values of estrogen receptor alpha and beta in patients with gastrooesophageal cancer: a meta-analysis. Medicine (Baltimore) 2019;doi:10.1097/MD.0000000000017934.

[25] Tang W, Liu R, Yan Y, et al. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget 2017;doi:10.18632/oncotarget.16582.

[26] Zhou F, Xu Y, Shi J, et al. Expression profile of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers. Cancer Med 2016;doi:10.1002/cam4.931.

[27] Matsu M, Kojima O, Kawakami S, et al. The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 1992;doi:10.1007/BF00308791.

[28] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;doi:10.3322/caac.21262.

[29] Ishigami H, Fujwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel Plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIXGC trial. J Clin Oncol 2018;doi:10.1200/JCO.2018.77.8613.

[30] Glehen O, Gilly FN, Ariviez C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;doi:10.1245/s10434-010-1039-7.

[31] Ettinger DS, Agulnik M, Cristea M, et al. Occult Primary. J Natl Compr Cancer Netw 2008;doi:10.6004/jnccn.2008.0078.

[32] Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunochemical cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: Ann Surg Oncol 2010;doi:10.1245/s10434-010-1039-7.

[33] De Lara S, Parris TZ, Werner Ronnerman E, et al. GATA3 as a putative biomarker of breast cancer metastasis—A retrospective immunohistochemical study. Breast J 2018;doi:10.1111/bjd.12863.

[34] Pentheroudakis G, Golimumab and anti-CD225 (GDCDFP-15) in confirming a breast origin for recurrent tumors. Breast 2010;doi:10.1016/j.breast.2010.02.007.

[35] De Lara S, Parris TZ, Werner Ronnerman E, et al. GATA3 as a putative marker of breast cancer metastasis—A retrospective immunohistochemical study. Breast J 2018;doi:10.1111/bjd.12863.

[36] De Lara S, Parris TZ, Werner Ronnerman E, et al. GATA3 as a putative marker of breast cancer metastasis—A retrospective immunohistochemical study. Breast J 2018;doi:10.1111/bjd.12863.